Article
Medicine, Research & Experimental
Wei Chong, Xingyu Zhu, Huicheng Ren, Chunshui Ye, Kang Xu, Zhe Wang, Shengtao Jia, Liang Shang, Leping Li, Hao Chen
Summary: This study elucidates the molecular heterogeneity of KRAS-mutant CRC and reveals new biological subtypes and therapeutic possibilities for these tumors.
Article
Oncology
Asimina Koulouridi, Michaela Karagianni, Ippokratis Messaritakis, Maria Sfakianaki, Alexandra Voutsina, Maria Trypaki, Maria Bachlitzanaki, Evangelos Koustas, Michalis Karamouzis, Anastasios Ntavatzikos, Anna Koumarianou, Nikolaos Androulakis, Dimitrios Mavroudis, Maria Tzardi, John Souglakos
Summary: The study reveals that KRAS G12D mutation is associated with better overall survival, while KRAS G12C mutation may indicate worse prognosis in terms of progression-free and overall survival. KRAS exon 3 and exon 4 mutations also have different impacts on progression-free and overall survival.
Article
Biology
Zaoqu Liu, Siyuan Weng, Qin Dang, Hui Xu, Yuqing Ren, Chunguang Guo, Zhe Xing, Zhenqiang Sun, Xinwei Han
Summary: This study introduces a new approach based on gene interaction networks to identify molecular subtypes of colorectal cancer (CRC) and suggests that this high-resolution taxonomy could help in the management of CRC patients. The study identifies six distinct subtypes with different features and analyzes their treatment sensitivity and prognosis.
Article
Oncology
Jianlei Wang, Jianping Song, Zeyang Liu, Tingxiao Zhang, Yanfeng Liu
Summary: This study investigates the prognostic value of tumor mutation burden (TMB) in colorectal cancer (CRC) and finds that high TMB indicates better prognosis for CRC patients with KRAS mutations. The study also develops a prognostic model using TMB as a predictive indicator, which shows good accuracy and potential clinical applications.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Alessandro Ottaiano, Mariachiara Santorsola, Paola Del Prete, Francesco Perri, Stefania Scala, Michele Caraglia, Guglielmo Nasti
Summary: High expression of CXCR4 is clearly associated with increased risk of death and progression in colorectal cancer. However, methodologic heterogeneity in CXCR4 assessment hinders direct translation into clinical practice, indicating the need for a consensus to streamline detection and scoring of CXCR4 expression in colorectal cancer.
Review
Biochemistry & Molecular Biology
Gongmin Zhu, Lijiao Pei, Hongwei Xia, Qiulin Tang, Feng Bi
Summary: KRAS is a commonly mutated oncogene in colorectal cancer, leading to aberrant activation of the KRAS protein and stimulation of downstream signaling pathways, resulting in cell proliferation and survival, ultimately leading to tumorigenesis. Patients with KRAS mutations in CRC have poor prognosis.
Article
Multidisciplinary Sciences
Hye Eun Park, Seung-Yeon Yoo, Nam-Yun Cho, Jeong Mo Bae, Sae-Won Han, Hye Seung Lee, Kyu Joo Park, Tae-You Kim, Gyeong Hoon Kang
Summary: Studies have shown that the prognostic effect of KRAS mutations on colorectal cancers varies depending on the type of mutation, with G12D/V mutations associated with shorter recurrence-free survival. Other codon 12 mutations and codon 13 mutations exhibit different trends.
SCIENTIFIC REPORTS
(2021)
Article
Biochemistry & Molecular Biology
Aleksandra Salagacka-Kubiak, Dawid Zawada, Lias Saed, Radzislaw Kordek, Agnieszka Jelen, Ewa Balcerczak
Summary: ABCG2 is a cell membrane pump encoded by the ABCG2 gene, which can protect cells against compounds initiating and/or intensifying neoplasia and is considered a marker of cancer stem cells. Its prognostic significance in colorectal cancer remains unclear. Using publicly available data, ABCG2 was shown to be underexpressed in colon and rectum adenocarcinomas, and this downregulation could result from the methylation level of some sites of the ABCG2 gene. However, no association was found between ABCG2 expression level and survival of colorectal cancer patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Yuanyuan Wang, Zhi Zhao, Jing Zhuang, Xinxin Wu, Zhizhong Wang, Bing Zhang, Ge Gao, Yinping Zhang, Caili Guo, Qingxin Xia
Summary: The high expression of the LC3 protein in CRC patients is associated with prognosis, and LC3, MSI status, and KRAS mutations are essential considerations in selecting adjuvant therapy for CRC. It helps to identify high-risk patients and explore more effective treatment options.
Review
Oncology
Yiqing Mao, Jiarong Lan
Summary: The geriatric nutritional risk index (GNRI) can serve as a valuable indicator for predicting the prognosis of colorectal cancer (CRC) patients undergoing surgery. Patients with low GNRI have poor overall and disease-free survival, as well as a higher risk of complications.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Danyang Wang, Qingmin Liu, Yanjun Ren, Yan Zhang, Xin Wang, Bing Liu
Summary: The study reveals abnormal expression of miR-143/145 and KRAS in colorectal cancer and suggests that genetic polymorphisms related to miRNA may have an impact on CRC development and progression. Certain genetic variations are associated with susceptibility to CRC and patient survival.
BIOSCIENCE REPORTS
(2021)
Article
Multidisciplinary Sciences
Mahsa Saliani, Razieh Jalal, Ali Javadmanesh
Summary: This study analyzed the transcriptional profiles of KRAS mutant and wild-type cell lines using RNA-seq data and bioinformatics methods. The results showed that KRAS signaling is an oncogenic signature in KRAS mutant cells. Furthermore, differentially-expressed genes were found to be involved in cancer-associated signal transduction pathways. Additionally, several differentially-expressed lncRNAs potentially regulate genes in the Rap1 and RAS signaling pathways.
SCIENTIFIC REPORTS
(2022)
Review
Oncology
Alessandro Ottaiano, Francesco Sabbatino, Francesco Perri, Marco Cascella, Roberto Sirica, Renato Patrone, Maurizio Capuozzo, Giovanni Savarese, Monica Ianniello, Nadia Petrillo, Luisa Circelli, Vincenza Granata, Massimiliano Berretta, Mariachiara Santorsola, Guglielmo Nasti
Summary: This review discusses the prognostic significance of the KRAS p.G12C mutation in metastatic colorectal cancer and highlights its potential as a promising therapeutic target. The aim is to increase awareness of the factors that can influence the clinical, prognostic, and therapeutic implications associated with distinct mutations within the same protein.
Article
Oncology
Karla Montalban-Hernandez, Ramon Cantero-Cid, Roberto Lozano-Rodriguez, Alejandro Pascual-Iglesias, Jose Avendano-Ortiz, Jose Carlos Casalvilla-Duenas, Gloria Cristina Bonel Perez, Jenny Guevara, Cristobal Marcano, Cristina Barragan, Jaime Valentin, Carlos del Fresno, Luis Augusto Aguirre, Eduardo Lopez Collazo
Summary: Among colorectal cancer patients, the level of soluble SIGLEC5 may serve as a potential prognostic marker and predictor of patient outcomes.
Article
Oncology
Tinghui Duan, Diyuan Zhou, Yizhou Yao, Xinyu Shao
Summary: This study found that FGF1 expression is elevated in CRC tissues, associated with poor prognosis, and linked to shorter survival time. FGF1 acts as a tumor activator in CRC and its expression is closely related to the mTOR-S6K1 pathway.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Joe Ibrahim, Ken Op de Beeck, Erik Fransen, Marc Peeters, Guy Van Camp
Summary: This study utilized DNA methylation data from the human epigenome to identify pan-cancer and tumor-specific CpG markers through a three-step computational approach. The identified markers can accurately differentiate between different cancer types and show promising applicability in new minimally invasive cancer detection assays.
MOLECULAR ONCOLOGY
(2022)
Letter
Oncology
Yana Debie, Timon Vandamme, Maria E. Goossens, Peter A. van Dam, Marc Peeters
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Otorhinolaryngology
Margot Baudelet, Frederic Duprez, Leen Van den Steen, Sandra Nuyts, Daan Nevens, Ann Goeleven, Caroline Vandenbruaene, Hanne Massonet, Alice Vergauwen, Heleen Bollen, Sarah Deschuymer, Kristien Wouters, Marc Peeters, Carl Van Laer, Steven Marien, Michiel Van den Brekel, Lisette van der Molen, Tom Vauterin, Joost van Dinther, Hilde Verstraete, Isabel Hutsebaut, Sabine Meersschout, Olivier Vanderveken, Marc De Bodt, Gwen Van Nuffelen
Summary: This multicenter RCT investigated the effect of three different service-delivery modes on patients' adherence to prophylactic swallowing exercises during radiotherapy. The study found that adherence decreased over time in all groups, but the therapist-supported group achieved the highest adherence rates. Increasing face-to-face contact with a speech-language therapist can overcome the problem of low adherence in this population.
Review
Oncology
Joe Ibrahim, Marc Peeters, Guy Van Camp, Ken Op de Beeck
Summary: The recent increase in cancer biomarker research has led to new insights in the field. Technological breakthroughs, such as long read sequencing and microarrays, have enabled high throughput profiling of biomarkers, while advances in bioinformatic tools have made reliable and accurate biomarkers a reality. These changes have renewed interest in biomarker research and provided opportunities for enhancing cancer management and early disease detection.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Yana Debie, Jonas R. M. Van Audenaerde, Timon Vandamme, Lieselot Croes, Laure-Anne Teuwen, Lise Verbruggen, Greetje Vanhoutte, Elly Marcq, Lisa Verheggen, Debbie Le Blon, Bart Peeters, Maria E. Goossens, Pieter Pannus, Kevin K. Arien, Sebastien Anguille, Annelies Janssens, Hans Prenen, Evelien L. J. Smits, Christof Vulsteke, Eva Lion, Marc Peeters, Peter A. van Dam
Summary: Patients with cancer have reduced humoral responses after double-dose COVID-19 vaccination, but their cellular response is comparable to healthy individuals. A third dose of BNT162b2 can boost immune responses in both healthy people and cancer patients. This study compares the effects of a third dose of BNT162b2 after homologous (double-dose BNT162b2) and heterologous (ChAdOx1) vaccination in cancer patients.
CLINICAL CANCER RESEARCH
(2023)
Letter
Oncology
Yana Debie, Peter A. van Dam, Maria E. Goossens, Marc Peeters, Timon Vandamme
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Oncology
Katleen Janssens, Chinouk Lambrechts, Barbara Geerinckx, Ken Op de Beeck, Guy Van Camp, Helena Oliveres, Hans Prenen, Timon Vandamme, Marc Peeters
Summary: One of the major challenges in digestive oncology is selecting the optimal therapy for RAS-mutated metastatic colorectal cancer (mCRC). Recent developments in targeting the RAS-pathway have shown promising results and may lead to clinical benefits for patients in the coming years. Although resistance remains a concern, strategic combination regimens have been developed to overcome this issue. In this review, we summarize the standard of care and discuss emerging therapies for RAS-mutated mCRC.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2023)
Article
Oncology
Marc Peeters, Hans-Peter Lipp, Minjeong Park, Ye Chan Yoon, Dirk Arnold
Summary: SB8 is a biosimilar of bevacizumab that has been extensively studied to demonstrate its similarity in various aspects. It is authorized for use in different types of tumors based on the concept of extrapolation. Additionally, SB8 offers the advantage of prolonged stability in diluted form compared to the reference bevacizumab. Although there are concerns about extrapolation, the "totality of evidence" supports the biosimilarity of SB8.
Article
Oncology
Katleen Janssens, Erik Fransen, Guy Van Camp, Hans Prenen, Ken Op de Beeck, Nancy Van Damme, Marc Peeters
Summary: This study provides evidence that left-sided colorectal cancer has a significantly better prognosis compared to right-sided colorectal cancer, in all stages and ages combined. The survival of left-sided colorectal cancer is also longer than right-sided colorectal cancer in stage IV, regardless of MMR, RAS, and BRAF status.
Article
Microbiology
Baptiste Oosterlinck, Hannah Ceuleers, Wout Arras, Joris G. De Man, Karen Geboes, Heiko De Schepper, Marc Peeters, Sarah Lebeer, Jurgita Skieceviciene, Georgina L. Hold, Juozas Kupcinskas, Alexander Link, Benedicte Y. De Winter, Annemieke Smet
Summary: This study identified the mucin-microbiome signatures in gastric adenocarcinomas and their impact on clinical outcomes. The findings showed that intestinal mucin phenotype and high-level MUC13 expression were associated with poor survival, while gastric MUC5AC or MUC6 abundance was associated with a more favorable outcome. Furthermore, oral bacteria such as Neisseria, Prevotella, and Veillonella were found to play a potential role in MUC13 signaling and were associated with intestinal and mixed mucin phenotype tumors.
Article
Chemistry, Medicinal
Danielle Delombaerde, Johan De Sutter, Lieselot Croes, Delphine Vervloet, Veronique Moerman, Nico van de Veire, Anne-Marie Willems, Kristien Wouters, Marc Peeters, Hans Prenen, Christof Vulsteke
Summary: The lack of solid data and prospective studies has resulted in a lack of clear guidelines for cardiovascular monitoring in patients receiving immune checkpoint inhibitors (ICIs). In order to address this issue, we have initiated the CAVACI trial to investigate the short- and long-term cardiovascular effects of ICIs. Patient recruitment started in January 2022.
Article
Oncology
Valerie Desmedt, Aranzazu Jauregui-Amezaga, Liselotte Fierens, Sandrine Aspeslagh, Jeroen Dekervel, Els Wauters, Marc Peeters, Joao Sabino, Lara Crape, Michael Somers, Anne Hoorens, Joris Dutre, Triana Lobaton
Summary: This paper provides updated practice advice on the diagnosis and management of immune checkpoint inhibitor-induced gastrointestinal toxicity for gastroenterologists and oncologists. The use of immune checkpoint inhibitors in cancer immunotherapy has been shown to increase overall survival, but it also carries the risk of severe immune-mediated adverse events, particularly involving the gastrointestinal tract. The paper emphasizes the importance of early multidisciplinary approach and proposes criteria for diagnosis and treatment.
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Microbiology
Estelle Meroc, Mark A. A. Fletcher, Germaine Hanquet, Mary P. E. Slack, Marc Baay, Kyla Hayford, Bradford D. D. Gessner, Lindsay R. R. Grant
Summary: Higher valency pneumococcal conjugate vaccines (PCV15 and PCV20) have been developed to tackle the disease burden caused by non-vaccine serotypes. This review provides an overview of the epidemiological characteristics of serotypes beyond PCV13, analyzing their association with different diseases and their antimicrobial non-susceptibility. The findings can contribute to informed decision-making regarding the choice and use of higher valency PCVs.
Review
Oncology
Laura Marien, Odeta Islam, Siddharth Chhajlani, Willem Lybaert, Marc Peeters, Guy Van Camp, Ken Op de Beeck, Timon Vandamme
Summary: Given the considerable heterogeneity in neuroendocrine neoplasms, there is a need for multiple biomarkers to capture different aspects of these tumors. Circulating biomarkers, such as NETest and ctDNA-based analysis, show promise in enhancing accuracy of diagnosis, prognosis determination, and therapy prediction and monitoring.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2023)
Article
Oncology
Katleen Janssens, Erik Fransen, Guy Van Camp, Hans Prenen, Ken Op de Beeck, Nancy Van Damme, Marc Peeters
Summary: This study confirms that left-sided colorectal cancer has a better prognosis compared to right-sided colorectal cancer in the Belgian population. The presence of biomarkers such as MMR, BRAF, and RAS status does not significantly affect the prognostic effect of primary tumor location.
